WHAT IS CLAIMED IS:

1. Gamma-hydroxybutyrate (GHB) or a salt thereof for use in the treatment of narcolepsy in a patient, wherein said patient is also taking or will be taking divalproex sodium,

wherein the GHB or a salt thereof is to be administered to the patient in a dose that is reduced by 10% to 40% to compensate for the effect caused by divalproex sodium,

wherein the dose of GHB or salt thereof when the patient is not taking the divalproex sodium is between 4.5 g to 9.0 g/day.

2. The GHB or salt thereof for use of claim 1, wherein the GHB or salt thereof is to be administered in a dose that is reduced by 15% to 25% to compensate for the effect caused by the divalproex sodium.

3. The GHB or salt thereof for use of claim 1, wherein the GHB or salt thereof is to be administered in a dose that is reduced by 20% to compensate for the effect caused by the divalproex sodium.

4. The GHB or salt thereof for use of any one of claims 1-3, wherein the GHB or salt thereof is prepared as a formulation which has a concentration of between 350 - 750 mg/ml.

5. The GHB or salt thereof for use of any one of claims 1-3, wherein the GHB or salt thereof is prepared as a formulation which has a concentration of between 450 - 550 mg/ml.

6. The GHB or salt thereof for use of any one of claims 1-5, wherein the GHB or salt thereof is prepared as a formulation which has a pH between 6 - 10.

7. The GHB or salt thereof for use of any one of claims 1-5, wherein the GHB or salt thereof is prepared as a formulation which has a pH between 6.5 - 8.

8. The GHB or salt thereof for use of any one of claims 1-7 wherein the salt comprises a single salt or a mixture of salts of GHB selected from a sodium salt of gamma-hydroxybutyrate (Na•GHB), a potassium salt of gamma-hydroxybutyrate (K•GHB), a magnesium salt of gamma-hydroxybutyrate ($Mg•(GHB)_2$), and a calcium salt of gamma-hydroxybutyrate ($Ca•(GHB)_2$).